← Eichor
Condition: Her2 Positive Advanced Breast Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Her2 Positive Advanced Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 · 40 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06625775Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT07014410Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer
Phase 2 · 1 location(s) · Yonsei University · NCT06837792Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea
Phase N/A · 1 location(s) · Seoul National University Hospital · NCT06928818Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06705127The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06254690Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and C
Phase 1/Phase 2 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT06298084Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Canc
Phase 3 · 31 location(s) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT07008976Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors,
Phase N/A · 1 location(s) · Hunan Cancer Hospital · NCT07073755Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/
Phase 1/Phase 2 · 14 location(s) · Ellipses Pharma · NCT05573126Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
Phase 2 · 1 location(s) · Brown University · NCT06974604A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestran
Phase 1/Phase 2 · 52 location(s) · Genentech, Inc. · NCT07100106A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Phase 1 · 4 location(s) · Cogent Biosciences, Inc. · NCT07383506At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860Exploration of the Safety and Efficacy of T-DXd Concurrent With Brain Radiotherapy in Patients With Brain Metastases HER
NA · 1 location(s) · QIAO LI · NCT07117864A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Phase 2 · 13 location(s) · Processa Pharmaceuticals · NCT06568692The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT05075512BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Phase 1 · 63 location(s) · BeOne Medicines · NCT06120283RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastati
Phase 2/Phase 3 · 109 location(s) · Hoffmann-La Roche · NCT07413939Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT07100600Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
Phase 3 · 203 location(s) · Celcuity Inc · NCT06757634The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study
Phase 1 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06770296Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
Phase 3 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06278870A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Ad
Phase 1 · 15 location(s) · TerSera Therapeutics LLC · NCT07310420Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced
Phase 2 · 2 location(s) · wanghaibo · NCT07285382Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
Phase 3 · 2 location(s) · InventisBio Co., Ltd · NCT06954961A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Gire
Phase 1 · 4 location(s) · Genentech, Inc. · NCT07214662A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other
Phase 1 · 7 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05461768
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.